KO-202125, a sauristolactam derivate, induces apoptosis to prevent KB human oral squamous carcinoma cells through inhibition of cyclooxygenase-2 expression

European Journal of Cancer Prevention

Volumn 19, Issue 1, 2010, Pages 23-30

  Leem, Dae Ho ^a   Choi, Kyeong Hee ^a   Han, Hye Suk ^a   Kim, Jun Hee ^a   Shin, Ji Ae ^a   Choi, Eun Sun ^a   Shim, Jung Hyun ^a   Kong, Gu ^b   Min, Yong Ki ^c   Nam, Jeong Seok ^d   Oh, Seung Hyun ^e   Kim, Kyoung A ^a   Kwon, Ki Han ^f   Cho, Nam Pyo ^a   Cho, Sung Dae ^a  

^a Chonbuk National University   (South Korea)

^b Hanyang University   (South Korea)

^c Korea Research Institute of Chemical Technology   (South Korea)

^d Gachon University   (South Korea)

^e National Cancer Center

^f Kwangju University   (South Korea)

Author keywords

Apoptosis; Celecoxib; Cyclooxygenase 2; KB human oral squamous carcinoma cells; KO 202125; PGE 2

Indexed keywords

ANTINEOPLASTIC AGENT; CELECOXIB; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; KO 202125; LIPOCORTIN 5; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROSTAGLANDIN E2; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CATALYSIS; CELL VIABILITY; CONTROLLED STUDY; DRUG POTENCY; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; MOUTH CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA;

ALKALOIDS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, SQUAMOUS CELL; CELL PROLIFERATION; CELL SURVIVAL; CYCLOOXYGENASE 2; DOWN-REGULATION; DRUG EVALUATION, PRECLINICAL; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; ISOINDOLES; KB CELLS; LACTAMS; MOUTH NEOPLASMS; PHENANTHRENES; PYRAZOLES; SULFONAMIDES;

EID: 75149141794     PISSN: 09598278     EISSN: None     Source Type: Journal    
DOI: 10.1097/CEJ.0b013e328333d09e     Document Type: Article

References (31)

1. Chan G, Boyle JO, Yang EK, Zhang F, Sacks PG, Shah JP, et al. (1999). Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck. Cancer Res 59:991-994. (Pubitemid 29135955)
2. Cho SD, Li G, Hu H, Jiang C, Kang KS, Lee YS, et al. (2005). Involvement of c-Jun N-terminal kinase in G2/M arrest and caspase-mediated apoptosis induced by sulforaphane in DU145 prostate cancer cells. Nutr Cancer 5 2:213-224.
3. Cho SD, Ahn NS, Jung JW, Yang SR, Park JS, Lee YS, et al. (2006). Critical role of the c-JunNH2-terminal kinase and p38 mitogen-activated protein kinase pathways on sodium butyrate-induced apoptosis in DU145 human prostate cancer cells. Eur J Cancer Prev 15:57-63.
4. Cho NP, Han HS, Soh Y, Son HJ (2007a). Overexpression of cyclooxygenase-2 correlates with cytoplasmic HuR expression in salivary mucoepidermoid carcinoma but not in pleomorphic adenoma. J Oral Pathol Med 36:297-303.
5. Cho NP, Han HS, Soh Y, Lee KY, Son HJ (2007b). Cytoplasmic HuR overexpression is associated with increased cyclooxygenase-2 expression in laryngeal squamous cell carcinomas. Pathology 39:545-550.
6. Choi SK, Seo BR, Lee KW, Cho W, Jeong SH, Lee KT (2007). Saucernetin-7 isolated from Saururus chinensis induces caspase-dependent apoptosis in human promyelocytic leukemia HL-60 cells. Biol Pharm Bull 30:1516-1522.
7. Dandekar DS, Lokeshwar BL (2004). Inhibition of cyclooxygenase (COX)-2 expression by Tet-inducible COX-2 antisense cDNA in hormone-refractory prostate cancer significantly slows tumor growth and improves efficacy of chemotherapeutic drugs. Clin Cancer Res 10:8037-8047.
8. Dannenberg AJ, Subbaramaiah K (2003). Targeting cyclooxygenase-2 in human neoplasia: rationale and promise. Cancer Cell 4:431-436.
9. Dannenberg AJ, Altorki NK, Boyle JO, Dang C, Howe LR, Weksler BB, Subbaramaiah K (2001). Cyclo-oxygenase 2: a pharmacological target for the prevention of cancer. Lancet Oncol 2:544-551. (Pubitemid 33586867)
10. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, Du Bois RN (1994). Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 107:1183-1188.
11. Hida T, Yatabe Y, Achiwa H, Muramatsu H, Kozaki K, Nakamura S, et al. (1998). Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res 58:3761-3764.
12. Hull MA (2005). Cyclooxygenase-2: how good is it as a target for cancer chemoprevention? Eur J Cancer 41:1854-1863.
13. Hwang BY, Lee JH, Jung HS, Kim KS, Nam JB, Hong YS, et al. (2003). Sauchinone, a lignin from Saururus chinensis, suppresses iNOS expression through the inhibition of transactivation activity of RelA of NF-kappaB. Planta Med 69:1096-1101.
14. Ko SH, Choi GJ, Lee JH, Han YA, Lim SJ, Kim SH (2008). Differential effects of selective cyclooxygenase-2 inhibitors in inhibiting proliferation and induction of apoptosis in oral squamous cell carcinoma. Oncol Rep 1 9:425-433.
15. Kwak YE, Jeon NK, Kim J, Lee EJ (2007). The cyclooxygenase-2 selective inhibitor celecoxib suppresses proliferation and invasiveness in the human oral squamous carcinoma. Ann N Y Acad Sci 1095:99-112.
16. Lee JH, Hwang BY, Kim KS, Nam JB, Hong YS, Lee JJ (2003). Suppression of RelA/p65 transactivation activity by a lignoid manassantin isolated from Saururus chinensis. Biochem Pharmacol 66:1925-1933.
17. Moon TC, Seo CS, Haa K, Kim JC, Hwang NK, Hong TG, et al. (2008). Mesodihydroguaiaretic acid isolated from Saururus chinensis inhibits cyclooxygenase- 2 and 5-lipoxygenase in mouse bone marrow-derived mast cells. Arch Pharm Res 31:606-610.
18. Oshima M, Dinchuk JE, Kargman SL, Oshima H, Hancock B, Kwong E, et al. (1996). Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 87:803-809.
19. Ristimaki A, Honkanen N, Jankala H, Sipponen P, Harkonen M (1997). Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res 5 7:1276-1280.
20. Sawhney M, Rohatgi N, Kaur J, Shishodia S, Sethi G, Gupta SD, et al. (2007). Expression of NF-kappaB parallels COX-2 expression in oral precancer and cancer: association with smokeless tobacco. Int J Cancer 120:2545-2556.
21. Shen J, Huang C, Jiang L, Gao F,Wang Z, Zhang Y, et al. (2007). Enhancement of cisplatin induced apoptosis by suberoylanilide hydroxamic acid in human oral squamous cell carcinoma cell lines. Biochem Pharmacol 73:1901-1909.
22. Soh JW, Weinstein IB (2003). Role of COX-independent targets of NSAIDs and related compounds in cancer prevention and treatment. Prog Exp Tumor Res 37:261-285.
23. Soldatenkov VA, Smulson M (2000). Poly(ADP-ribose) polymerase in DNA damage-response pathway: implications for radiation oncology. Int J Cancer 9 0:59-67.
24. Song SY, Lee I, Park C, Lee H, Hahm JC, Kang WK (2005). Neolignans from Saururus chinensis inhibit PC-3 prostate cancer cell growth via apoptosis and senescence-like mechanisms. Int J Mol Med 16: 5 17-523.
25. Sumitani K, Kamijo R, Toyoshima T, Nakanishi Y, Takizawa K, Hatori M, Nagumo M (2001). Specific inhibition of cyclooxygenase-2 results in inhibition of proliferation of oral cancer cell lines via suppression of prostaglandin E2 production. J Oral Pathol Med 30:41-47.
26. Thun MJ, Henley SJ, Patrono C (2002). Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 94:252-266.
27. Tiano HF, Loftin CD, Akunda J, Lee CA, Spalding J, Sessoms A, et al. (2002). Deficiency of either cyclooxygenase (COX)-1 or COX-2 alters epidermal differentiation and reduces mouse skin tumorigenesis. Cancer Res 6 2:3395-3401.
28. Wilson KT, Fu S, Ramanujam KS, Meltzer SJ (1998). Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated adenocarcinomas. Cancer Res 58:2929-2934.
29. Xu K, Shu HK (2007). EGFR activation results in enhanced cyclooxygenase-2 expression through p38 mitogen-activated protein kinase-dependent activation of the Sp1/Sp3 transcription factors in human gliomas. Cancer Res 6 7:6121-6129.
30. Zha S, Yegnasubramanian V, Nelson WG, Isaacs WB, De Marzo AM (2004). Cyclooxygenases in cancer: progress and perspective. Cancer Lett 215:1-20.
31. Zhang D, Li J, Song L, Ouyang W, Gao J, Huang C (2008). A JNK1/AP-1-dependent, COX-2 induction is implicated in 12-O-tetradecanoylphorbol- 13-acetate-induced cell transformation through regulating cell cycle progression. Mol Cancer Res 6:165-174.